FDA Clinical Hold Knocks REGENXBIO Stock

REGENXBIO Inc. (NASDAQ:RGNX) shares are tumbling on Wednesday with a session volume of 3.83 million versus an average volume of 684.271 thousand.The move follows a regulatory update that has raised concerns among investors. The U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapies.FDA Holds REGENXBIO’s Gene Therapy ProgramsThe FDA’s decision affects REGENXBIO’s RGX-111 and RGX-121 programs, which are aimed at treating rare genetic disorders.The clinical hold wa ...